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Investigation of the eff ects of vitamin D and calcium
on intestinal motility: In vitro tests and implications
for clinical treatment
The presence of vitamin D receptors in small intestine mus-
cle cells may lead one to think that vitamin D may act lo-
cally, infl uencing intracellular calcium concentration and 
contributing to the contraction-relaxation regulation of the 
intestinal smooth muscle cells. This study investigates the 
potential eff ects of vitamin D and calcium on intestinal mo-
tility using an in vitro test. 
Diff erent calcium concentrations added to the tissue not 
pre-treated with 1,25-dihydroxycholecalciferol [1a,25(OH)2D3] 
produced no response at low doses (1.25 ´  10–3 and 2.0 ´  10–3 
mol L–1) and only a very weak response at higher concen-
tration (3.0 ´ 10–3 mol L–1). The addition of 1a,25(OH)2D3 
(1.44 ´  10–10 mol L–1) had no eff ect on isolated ileum motility. 
When calcium (3.0 ´ 10–3 mol L–1) was added aft er at least 3 
hours, it evoked evident and persistent contractions for 
60–90 minutes. The contractions were at about 40 % of the 
peak produced by acetylcholine. Thus, simultaneous intake 
of vitamin D and calcium might be a useful co-adjuvant in 
intestinal atony therapy aimed to stimulate normal gut mo-
tility in humans. These fi ndings imply that supplemental 
vitamin D may be important in all cases where calcium has 
to be prescribed.
Keywords: vitamin D, calcium, intestinal motility, in vitro 
tests
Vitamin D is a group of fat-soluble compounds that include ergocalciferol (vitamin D2) 
and cholecalciferol (vitamin D3). The most abundant form of vitamin D is its hydroxylation 
product in liver, 25-hydroxy-vitamin D3 [25(OH)D3], whose serum concentration is used to 
indicate the vitamin D status of a human individual. The most active metabolite is ob-
tained from further hydroxylation of 25(OH)D3 in the kidney to 1a,25-dihydroxy-vitamin 
D3 [1a,25(OH)2D3] (1, 2).
Health consequences of vitamin D defi ciency are important; recent studies confi rm 
that vitamin D defi ciency is widespread in children and elderly people (3, 4). Vitamin D 
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defi ciency has also been implicated in the pathogenesis of certain cancers, including 
breast, ovarian, prostate, and colon, and of other diseases, for example multiple sclerosis, 
diabetes, Lupus erythematosus, cardiovascular diseases, and hypertension (5–7).
Two major signal transduction pathways activated by 1a,25(OH)2D3 in target cells 
have been identifi ed:  the so-called genomic pathway, where the nuclear receptors play a 
major role, and the non-genomic signal transduction pathway. In order to ensure full bio-
logical activity of 1a,25(OH)2D3 both pathways need to be activated. The non-genomic 
pathway is faster than that induced following changes in gene expression. It induces rapid 
changes in intracellular calcium concentrations, alterations in membrane phospholipid 
metabolism and it activates several signalling transduction pathways (8).
Biological eff ects induced by the active form of 1a,25(OH)2D3 are mediated by the vi-
tamin D receptor (VDR), also known as the NR1I1 receptor. This receptor belongs to the 
superfamily of the nuclear receptor (NR), which includes receptors for steroid hormones, 
retinoids and thyroid hormones (9).
The presence of the receptor outside the classical target tissues, even in the small in-
testine muscle cells, may imply that vitamin D acts locally, infl uencing the intracellular 
calcium concentration and participating in contraction-relaxation regulation of the intes-
tinal smooth muscle cell.
The aim of this study is to investigate the potential eff ects of vitamin D and calcium 
on intestinal motility using an in vitro test.
EXPERIMENTAL
Chemicals and reagents 
The following reagents were used: NaCl, USP grade (Research Organic, Inc., USA), 
KCl (Carlo Erba Reagenti s.r.l., Italy), CaCl2 ´ 2H2O (Merck, Germany), NaHCO3, ACS re-
agent (Research Organic), MgCl2 ´ 6H2O (Merck), NaH2PO4 ´ H2O (Merck), D(+) glucose 
(Merck), acetylcholine chloride (TCI Europe, Belgium) and 1a,25(OH)2D3, 99 % TLC (Sig-
ma-Aldrich Inc., USA).
Tyrode’s solution. – It was composed of NaCl (137 mmol L–1), KCl (2.7 mmol L–1), CaCl2 
´ 2H2O (1.8 mmol L–1), NaHCO3 (11.9 mmol L–1), MgCl2 ´  6H2O (1.05 mmol L–1), NaH2PO4 (0.4 
mmol L–1), D(+) glucose  (5.55 mmol L–1). 
Instruments
The following instruments were used: Isotonic Transducer no 7006 calibrated to ten-
sion of 1 g (Ugo Basile S.p.A, Italy), recording device ‘UNIRECORD’ for transducer: model 
7050 Serial. n. 86503 (Ugo Basile), isolated organ bath, model 4050. Serial No. 00387 – 2 
Chamber (Ugo Basile S.p.A.), O2 (95 %) and CO2 (5 %) tanks (Linde – Arluno, Italy).
Animals, tissue preparation and in vitro tools
The experimental procedure has been described previously (10). Six male guinea-
pigs weighing 300–400 g (aged 2–3 months, provided by Morini, Italy) were housed in 
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groups with food and water available ad libitum, in a room with controlled temperature 
(22 ± 1 °C) and under artifi cial 12-h light/12-h dark cycle for at least 4 days before use. 
The ileum was excised and kept in Tyrode’s solution. Each segment, 2–3 cm long, was 
cleaned and set up under 1 g tension in a 10-mL organ bath containing Tyrode’s solution, 
maintained at 37 °C and gassed with 95 % O2 and 5 % CO2. Changes in tension were 
recorded under isotonic conditions by a transducer connected to a recorder, which was 
calibrated before each experiment. The preparations were allowed to equilibrate for 
30–40 min and were then stimulated two or three times with ACh (10−7 mol L–1) to ascer-
tain their responses. Contractile responses recorded by the transducer were expressed 
as percentage of the ACh maximum response. The same tissue preparations were gener-
ally used for several consecutive tests.  Aft er each test, the preparations were allowed to 
rest for 25 min and were washed three times between tests with Tyrode’s solution. Each 
experimental test was performed on tissue preparations coming from at least four ani-
mals. A series of in vitro tests was designed to investigate the potential eff ects of 
1a,25(OH)2D3 and calcium (CaCl2 ´ 2H2O) on intestinal motility. Acetylcholine chloride 
served as a reference substance.
The experimental procedure was approved by the University Ethics Committ ee “La 
Sapienza” concerning the care and use of mammals in experimental practice.
*washing; c(ACh) = 1.1 ´ 10–7 mol L–1.
Fig. 1. Response to diff erent concentrations of calcium (Ca1 = 1.25 ´ 10–3 mol L–1; Ca2 = 2.0 ´ 10–3 mol L–1; 
Ca3 = 3.0 ´  10–3 mol L–1) of the isolated guinea pig ileum strip without pre-treatment with 1a,25(OH)2D3.
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RESULTS AND DISCUSSION
Eff ect of calcium concentration on isolated guinea pig ileum not pre-treated with 
1a,25(OH)2D3
Diff erent concentrations of calcium added to the tissues not pre-treated with 
1a,25(OH)2D3 gave no response at low doses (Ca1: 1.25 ´ 10–3 mol L–1 and  Ca2: 2.0 ´ 10–3 mol 
L–1) and only a very weak response at higher concentration (Ca3: 3.0 ´ 10–3 mol L–1) (Fig. 1). 
The lack of response to calcium could be due to the inability of this ion to enter the cell, 
bind the contracting proteins and trigger contraction mechanisms (Fig. 1).
Eff ect of calcium on the motility of isolated guinea pig ileum pre-treated with 
1a,25(OH)2D3
Addition of 1a,25(OH)2D3 (1.44 ´ 10–10 mol L–1) had no eff ect on isolated ileum motility. 
As shown in Fig. 2, the tissue kept its stable basal contraction for hours.
However, aft er at least 3 hours, when calcium (Ca3: 3.0 ´ 10–3 mol L–1) was added, 
evident contractions were evoked and persisted for 60–90 minutes, until the tissue was 
*washing; c(ACh) = 1.1 ´ 10–7 mol L–1.
Fig. 2. Response of the isolated guinea pig ileum strip to 1a,25(OH)2D3 (1.44 ´ 10–10 mol L–1) followed 
by calcium (Ca3 = 3.0 ´ 10–3 mol L–1).
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washed with Tyrode’s solution to remove the tested substances. The mean percent con-
traction was 39.1 ± 4.1 (mean ± SD, six experiments) of peak of acetylcholine contraction 
(Fig. 2).
Experiments were also performed using diff erent calcium concentrations (Ca2: 2.0 ´ 
10–3mol L–1   and Ca4: 2.5 ´ 10–3mol L–1), in diff erent tissues (six guinea pig ileums for each 
concentration), maintaining unchanged the time and modality of 1a,25(OH)2D3 pre-addition 
(1.44 ´ 10–10 mol L–1, contact time more than 3 hours). Calcium-evoked contractions (mean ± 
SD, six experiments) were 31.1 ± 3.4 for Ca2 and 37.0 ± 3.4 % for Ca4 of the recorded acetylcho-
line contraction peak (Fig. 3). 
The results confi rm the role of vitamin D in guinea pig ileum muscle cell contractility. 
Calcium infl ux in the smooth muscle cell seems to be favoured in tissues pre-treated with 
1a,25(OH)2D3 and it is followed by contractions evoked by its interaction with proteins 
specifi cally involved in the contraction (11).  Calcium triggers the contraction process; in 
fact, this happens aft er it is in the cell and its intracellular concentration is enhanced, acti-
vating the muscle contraction. 
This late eff ect seems to be due to genomic response rather than non-genomic activity 
on intestinal smooth muscle. Reported data confi rm that vitamin D promotes calcium 
transfer into the cell (11). The contracting activity is a function of intracellular calcium 
*washing; c(ACh) = 1.1 ´ 10–7 mol L–1.
Fig. 3. Response to diff erent concentrations of calcium (Ca4 = 2.5 ´ 10–3 mol L–1; Ca2 = 2.0 ´ 10–3 mol L–1) 
of the isolated guinea pig ileum strip pre-treated with 1a,25(OH)2D3 (1.44 ´ 10–10 mol L–1).
348
G. Giraldi  et al.: Investigation of the eff ects of vitamin D and calcium on intestinal motility: In vitro tests and implications for clinical 
treatment, Acta Pharm. 65 (2015) 343–349.
 
concentration. This, in turn, is determined by h omeostatic mechanisms operating within 
the cells, which act on membrane channels, transporters and ATP dependent pumps. We 
found that 1a,25(OH)2D3 may be included among these mechanisms and the indirect role 
of vitamin D on isolated guinea pig ileum contractility was confi rmed in our research 
because it promoted the response to calcium. 
1a,25(OH)2D3 stimulates calcium absorption, increasing permeability at the intestinal 
level and active transport. In addition, 1a,25(OH)2D3 modifi es the binding between 
calmodulin and myosin I, a protein found in the intestinal villous (12). The binding of 
calmodulin to myosin promotes calcium entrance into the intestinal cells, while transport 
within the cytoplasm is ensured by calbindin D, whose synthesis is stimulated by cal-
citriol itself. Calbindin D is a low molecular mass protein; increased synthesis of calbindin 
D results in extended absorption of calcium. The calbindin calcium binding domain is 
similar to that of calmodulin (12). 
The relationship between the intracellular calcium level and contraction evoked is 
due to the action of ACh on muscarinic receptors located in intestinal smooth muscle cells 
(muscarinic acetylcholine receptor M3) (13). The binding of ACh to its receptor triggers a 
G protein with the production of inositol 1,4,5-triphosphate (IP3). The opening of calcium 
channels in the endoplasmic reticulum increases calcium levels in the cytoplasm. Calcium 
binds the troponin belonging to the troponin-tropomyosin system. This complex causes 
the actin to bind to the myosin fi lament which produces the contraction. All these mecha-
nisms could be applied to our results to emphasize the role of the vitamin in the contrac-
tion process.
CONCLUSIONS
Calcium added to isolated guinea pig ileum not pre-treated with 1α,25(OH)2D3 
showed no response, probably because the calcium membrane transporters were scarcely 
expressed or the calcium channels were inactivated and the ion was not able to enter the 
cells. However, when 1α,25(OH)2D3 was added, followed aft er at least 3 hours by calcium, 
the response to this ion was evident. 1a,25(OH)2D3 can increase the synthesis of the calci-
um channel in the cell. In addition, other preliminary results, which are not shown, indi-
cated a potential cholinergic modulation. The main strength of our study was to show that 
vitamin D has an indirect role in the mechanism of contraction. However, further studies 
are needed to clarify the role of the receptors involved in the mechanism of action of vita-
min D. The current results suggest that supplemental vitamin D and calcium may be use-
ful co-adjuvants in intestinal atony therapy, stimulating normal intestinal motility.
REFERENCES
 1.  D. D. Bikle, Vitamin D metabolism, mechanism of action, and clinical applications, Chem. Biol. 21 
(2014) 319–329; DOI: 10.1016/j.chembiol.2013.12.016.
 2.  C. Carlberg, S. Seuter and S. Heikkinen, The fi rst genome-wide view of vitamin D receptor loca-
tions and their mechanistic implications, Anticancer Res. 32 (2012) 271–282.
 3.  E. De Luca d’Alessandro, S. Bonacci and G. Giraldi, Aging populations: the health and quality of 
life of the elderly, Clin. Ter. 162 (2011) e13-e18.
349
G. Giraldi  et al.: Investigation of the eff ects of vitamin D and calcium on intestinal motility: In vitro tests and implications for clinical 
treatment, Acta Pharm. 65 (2015) 343–349.
 
 4.  A. Prentice, Vitamin D defi ciency: a global perspective, Nutr. Rev. 66 (10 Suppl. 2) (2008) S153-S164; 
DOI: 10.1111/j.1753-4887.2008.00100.x. 
 5.  W. B. Grant, Epidemiology of disease risks in relation to vitamin D insuffi  ciency, Prog. Biophys. 
Mol. Biol. 92 (2006) 65–79; DOI: 10.1016/j.pbiomolbio.2006.02.013.
 6.  R. Przybylski, S. McCune, B. Hollis and R. U. Simpson, Vitamin D defi ciency in the spontane-
ously hypertensive heart failure [SHHF] prone rat, Nutr. Metab. Cardiovasc. Dis. 20 (2010) 641–646; 
DOI: 10.1016/j.numecd.2009.07.009.
 7.  G. Giraldi, E. De Luca d’Alessandro, A. Mannocci, V. Vecchione and L. Martinoli, A pilot study of 
the eff ect of pantothenic acid in the treatment of post-operative ileus: results from an orthopedic 
surgical department, Clin. Ter. 163 (2012) e121-e126.
 8.  M. R. Haussler, P. W. Jurutka, M. Mizwicki and A. W. Norman, Vitamin D receptor (VDR)-medi-
ated actions of 1α,25(H)₂vitamin D₃: genomic and non-genomic mechanisms, Best Pract. Res. Clin. 
Endocrinol. Metab. Endocrinol. Metab. 25 (2011) 543–559. 
 9.  Y. Wang, J. Zhu and H. F. DeLuca, Where is the vitamin D receptor? Arch. Biochem. Biophys. 523 
(2012) 123–133; DOI: 10.1016/j.abb.2012.04.001.
10.  P. Marini, L. Romanelli, D. Valeri, P. Tucci, P. Valeri and M Palmery, Acute withdrawal induced by 
adenosine A-receptor activation in isolated guinea-pig ileum: role of opioid receptors and eff ect 
of cholecystokinin, J. Pharm. Pharmacol. 62 (2010) 622–632.
11.  J. W. Pike and M. B. Meyer, The vitamin D receptor: new paradigms for the regulation of gene 
expression by 1,25-dihydroxyvitamin D(3), Endocrinol. Metab. Clin. North Am. 39 (2012) 255–269; 
DOI: 10.1016/j.ecl.2010.02.007.
12.  S. Christakos, Mechanism of action of 1,25-dihydroxyvitamin D3 on intestinal calcium absorp-
tion, Rev. Endocr. Metab. Disord. 13 (2012) 39–44; DOI: 10.1007/s11154-011-9197-x.
13.  R. M. Eglen, S. S. Hedge and N. Watson, Muscarinic receptor subtypes and smooth muscle func-
tion, Pharmacol. Rev. 48 (1996) 531–565.
